Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

Recombinant Nipah Virus Post-Fusion Glycoprotein (NIV pF) antibody

This Mouse Monoclonal antibody specifically detects in ELISA and WB. It exhibits reactivity toward Nipah Virus (NiV).
Catalog No. ABIN7824739

Quick Overview for Recombinant Nipah Virus Post-Fusion Glycoprotein (NIV pF) antibody (ABIN7824739)

Target

Nipah Virus Post-Fusion Glycoprotein (NIV pF)

Antibody Type

Recombinant Antibody

Reactivity

Nipah Virus (NiV)

Host

  • 1
Mouse

Clonality

  • 1
Monoclonal

Conjugate

  • 1
Un-conjugated

Application

ELISA, Western Blotting (WB)

Clone

3C3
  • Expression System

    HEK293

    Purpose

    Monoclonal Anti-Nipah Post Fusion glycoprotein Antibody, Human IgG1 (3C3) (MALS verified)

    Characteristics

    Monoclonal Anti-Nipah Post Fusion glycoprotein Antibody, Human IgG1 (3C3) is a chimeric monoclonal antibody recombinantly expressed from HEK293, which combines the variable region of a mouse monoclonal antibody with Human constant domain.

    Purification

    Protein A purified / Protein G purified

    Purity

    95% as determined by SDS-PAGE.

    Sterility

    0.22 μm filtered

    Isotype

    IgG1, kappa
  • Application Notes

    ELISA: 0.03-16 ng/ml; Western Blot: 0.05-10 µg/ml

    Restrictions

    For Research Use only
  • Format

    Lyophilized

    Buffer

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Handling Advice

    Please avoid repeated freeze-thaw cycles.

    Storage

    -20 °C,-80 °C

    Storage Comment

    For long term storage, the product should be stored at lyophilized state at -20°C or lower. This product is stable after storage at: -20°C to -70°C for 12 months in lyophilized state; -70°C for 3 months under sterile conditions after reconstitution.
  • Target

    Nipah Virus Post-Fusion Glycoprotein (NIV pF)

    Alternative Name

    Nipah Virus Post-Fusion Glycoprotein

    Background

    Hendra virus (HeV) and Nipah virus (NiV) are henipaviruses discovered in the mid-to late 1990s that possess a broad host tropism and are known to cause severe and often fatal disease in both humans and animals. HeV and NiV infect host cells through the coordinated efforts of two envelope glycoproteins. The G glycoprotein attaches to cell receptors, triggering the fusion (F) glycoprotein to execute membrane fusion. G is a type II homotetrameric transmembrane protein responsible for binding to ephrinB2 or ephrinB3 (ephrinB2/B3) receptors. F is a homotrimeric type I transmembrane protein that is synthesized as a premature F0 precursor and cleaved by cathepsin L during endocytic recycling to yield the mature, disulfide-linked, F1 and F2 subunits. Upon binding to ephrinB2/B3, NiV G undergoes conformational changes leading to F triggering and insertion of the F hydrophobic fusion peptide into the target membrane. Subsequent refolding into the more stable post-fusion F conformation drives merger of the viral and host membranes to form a pore for genome delivery to the cell cytoplasm.
You are here:
Chat with us!